2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0830R
    Palmitic acid (Standard) 57-10-3 98.31%
    Palmitic acid (Standard) is the analytical standard of Palmitic acid. This product is intended for research and analytical applications. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid (Standard)
  • HY-P3414A
    Proteasome-activating peptide 1 TFA 99.82%
    Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis.
    Proteasome-activating peptide 1 TFA
  • HY-100234A
    DREADD agonist 21 dihydrochloride 2250025-92-2 98.94%
    DREADD agonist 21 dihydrochloride is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist (EC50=1.7 nM).
    DREADD agonist 21 dihydrochloride
  • HY-113468A
    3-O-Methyldopa 300-48-1 ≥98.0%
    3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease.
    3-O-Methyldopa
  • HY-114118F
    Semaglutide, FITC labeled
    Semaglutide, FITC labeled is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
    Semaglutide, FITC labeled
  • HY-W002112
    (±)-Nornicotine 5746-86-1
    (±)-Nornicotine is the primary metabolite of nicotine that is formed through demethylation of nicotine in the genus Nicotiana tabacum L. (±)-Nornicotine is a precursor of tobacco-specific nitrosamine N-nitrosonornicotine. (±)-Nornicotine has detrimental effects to human health.
    (±)-Nornicotine
  • HY-W016715
    L-Cysteine hydrochloride hydrate 7048-04-6 ≥98.0%
    L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and insulin and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes.
    L-Cysteine hydrochloride hydrate
  • HY-16312
    MDL-29951 130798-51-5 99.17%
    MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with Ki of 0.14 μM for [3H]glycine binding in vitro and in vivo.
    MDL-29951
  • HY-18099A
    S1RA hydrochloride 1265917-14-3 99.94%
    S1RA (E-52862) hydrochloride is an orally active and selective sigma-1 receptor (σ1R) antagonist with a Ki value of 17 nM. S1RA hydrochloride shows good selectivity against σ2R (Ki >1000 nM). S1RA hydrochloride is a human 5-HT2B receptor antagonist with an IC50 value of 4.7 μM. S1RA hydrochloride inhibits neuropathic pain and activity-induced spinal sensitization.
    S1RA hydrochloride
  • HY-15441
    Edelinontrine 1082744-20-4 99.85%
    Edelinontrine (PF-04447943) is a potent inhibitor of human recombinant PDE9A (IC50=12 nM) with >78-fold selectivity, respectively, over other PDE family members (IC50>1000 nM).
    Edelinontrine
  • HY-130121
    MK-8719 1382799-40-7 99.55%
    MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (Ki=7.9 nM for hOGA) with excellent CNS penetration.
    MK-8719
  • HY-14174
    MRK-560 677772-84-8 ≥99.0%
    MRK-560 is an orally active, brain barrier-penetrated γ-Secretase inhibitor, reducing Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 decreases mutant NOTCH1 processing by selectively inhibiting PSEN1. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL).
    MRK-560
  • HY-100673
    LM22A-4 37988-18-4 ≥98.0%
    LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.
    LM22A-4
  • HY-107512
    Kynurenic acid sodium 2439-02-3 99.79%
    Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.
    Kynurenic acid sodium
  • HY-114237
    GDC-0276 1494581-70-2 99.95%
    GDC-0276 is a potent, selective, reversible and orally active NaV1.7 inhibitor with an IC50 value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects.
    GDC-0276
  • HY-12850A
    Dasotraline hydrochloride 675126-08-6 99.04%
    Dasotraline hydrochloride (SEP-225289 hydrochloride) is a triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters with IC50 values of 4, 6, and 11 nM, respectively.
    Dasotraline hydrochloride
  • HY-P1240B
    Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate 99.82%
    Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) acetate is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate has encephalitogenic activity and induces T?cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate produces a relapsing-remitting neurological disease with extensive plaque-like demyelination.
    Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate
  • HY-14127
    R121919 195055-03-9 99.53%
    R121919 (NBI30775) is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats.
    R121919
  • HY-15728
    Radotinib 926037-48-1 98.92%
    Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.
    Radotinib
  • HY-N0925
    Tetrahydroberberine 522-97-4 98.61%
    Tetrahydroberberine is a different kind of living thing that can be extended and divided into parts. Tetrahydroberberine is a kind of effective D2 receptor antagonistic force. Tetrahydroberberine has the ability to strengthen the stomach and relieve the pressure on the stomach.
    Tetrahydroberberine
Cat. No. Product Name / Synonyms Application Reactivity